Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience

Abstract

Objective:

Onabotulinumtoxin-A has been approved for wet overactive bladder refractory to anticholinergics in randomised controlled trials; however, data from real-life practice are scarce. This study was designed to assess the efficacy of intravesical onabotulinumtoxin-A injections, focusing on health status, urinary symptoms and subjective satisfaction.

Methods:

Data from consecutive patients with overactive bladder-refractory to anticholinergics treated with onabotulinumtoxin-A were prospectively collected and analysed. Standard doses (100–150 U) were used, followed by repeat sessions when clinical benefits diminished. Efficacy and safety of repeat onabotulinumtoxin-A administrations were assessed at 12-week post-injection. Clinical parameters evaluated were: change in the magnitude and frequency of incontinence, urgency and nocturia episodes, change in the number of pads used and procedural complications. Quality of life was evaluated using the 36-Item Short-Form Health Survey, Overactive Bladder Screener and Treatment Benefit Scale questionnaires.

Results:

Consecutive overactive bladder-refractory to anticholinergics patients (n = 22) (median duration of oral therapy: 10 months) were enrolled. No intraoperative complications occurred, but two urinary retention cases were recorded. Forty-five percent of patients (10/22) were re-treated (median duration of perceived benefits: 18 months, range: 8–55 months). The number of urinary incontinence, frequency and nocturia episodes, and pads used went from 3.6, 11.3, 2.7 and 2.4 preoperatively to 1.0, 5.8, 0.7 and 0.7 postoperatively (p < 0.005). Quality of life (36-Item Short-Form Health Survey) was significantly improved and symptom scores (Overactive Bladder Screener) were reduced, from 34.5 to 17.1 at week 12 (p < 0.05). Eighty-seven percent of patients indicated improvement/great improvement in their condition (Treatment Benefit Scale).

Conclusion:

Intradetrusor injections of onabotulinumtoxin-A in patients with overactive bladder-refractory to anticholinergics significantly improved health status and urinary symptoms, with high subjective satisfaction.

Keywords

OnabotulinumtoxinA anticholinergics overactive bladder detrusor over-activity quality of life 36-Item Short-Form Health Survey

Get full access to this article

View all access options for this article.

References

Abrams

Cardozo

Fall

et al . The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167–787.

Stewart

Van Rooyen

Cundiff

et al . Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327–336.

Hashim

HAP

. Overactive bladder: an update. Curr Opin Urol 2007; 17: 231–236.

Coyne

Sexton

Irwin

et al . The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008; 101: 1388–1395.

Onukwugha

Zuckerman

McNally

et al . The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care 2009; 15: S90–S97.

Chapple

Khullar

Gabriel

et al . The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543–562.

Chapple

Cardozo

Nitti

et al . Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn 2014; 33: 17–30.

Wagg

Franks

Ramos

et al . Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J 2015; 9: 343–350.

Sexton

Notte

Maroulis

et al . Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011; 65: 567–585.

10.

Lucas

MGBR

Cruz

et al . EAU guidelines on urinary incontinence. Arnhem: European Association of Urology, 2015.

11.

Gormley

Lightner

Faraday

et al . Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015; 193: 1572–1580.

12.

Mangera

Apostolidis

Andersson

et al . An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol 2014; 65: 981–990.

13.

Chapple

Sievert

MacDiarmid

et al . OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 2013; 64: 249–256.

14.

Nitti

Dmochowski

Herschorn

et al . OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 2013; 189: 2186–2193.

15.

Abrams

Artibani

Cardozo

et al . Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2009; 28: 287.

16.

Brazier

Harper

Jones

et al . Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305: 160–164.

17.

McHorney

Ware

Jr Raczek

et al . The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247–263.

18.

Coyne

Margolis

Bavendam

et al . Validation of a 3-item OAB awareness tool. Int J Clin Pract 2011; 65: 219–224.

19.

Colman

Chapple

Nitti

et al . Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. Urology 2008; 72: 803–807.

20.

Ware

Kosinski

Bjorner

et al . User’s manual for the SF-36v2 health survey. 2nd ed. Lincoln, RI: QualityMetric Incorporated, 2007.

21.

Benner

Nichol

Rovner

et al . Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010; 105: 1276–1282.

22.

Cornu

. Actual treatment of overactive bladder and urge urinary incontinence. Minerva Urol Nefrol 2013; 65: 21–35.

23.

Fowler

Auerbach

Ginsberg

et al . OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol 2012; 62: 148–157.

24.

Ruff

Bagshaw

Aracil

et al . Economic impact of onabotulinumtoxinA for overactive bladder with urinary incontinence in Europe. J Med Econ 2016; 19: 1107–1115.

25.

Anger

Weinberg

Suttorp

et al . Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol 2010; 183: 2258–2264.

26.

Rovner

Kennelly

Schulte-Baukloh

et al . Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 2011; 30: 556–562.

27.

Giannantoni

Carbone

Carone

et al . Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement. World J Urol 2017; 35: 299–306.

28.

Giannantoni

Proietti

Costantini

et al . OnabotulinumtoxinA intravesical treatment in patients affected by overactive bladder syndrome: best practice in real-life management. Urologia 2015; 82: 179–183.

29.

Marcelissen

Rahnama’i

Snijkers

et al . Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms. World J Urol 2017; 35: 307–311.

30.

Dowson

Watkins

Khan

et al . Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol 2012; 61: 834–839.

31.

Sahai

Dowson

Khan

et al . Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 2009; 103: 1509–1515.

32.

Kalsi

Apostolidis

Popat

et al . Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006; 49: 528–535.

33.

Cui

Zhou

Zong

et al . The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: a systematic review and meta-analysis. Neurourol Urodyn 2015; 34: 413–419.

34.

Onem

Bayrak

Demirtas

et al . Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: first multicentric study in Turkish population. Neurourol Urodyn 2017; 37: 263–268.